Ready to use porcine vaccine
The invention relates to certain methods for the determination of an antigen content of a first antigen in a mixture comprising two or more antigens. The invention also relates to a potency test for an antigen in a combination vaccine. The method allows the determination of the antigen content in a mixture additionally comprising antibodies that are capable of binding with the antigen.
1. A ready to use vaccine comprising a porcine circovirus type 2 (PCV-2) antigen and a Mycoplasma hyopneumoniae ( M. hyo ) antigen;
wherein the M. hyo antigen originates from media comprising serum that also contains an antibody that is capable of binding to the PCV-2 antigen; wherein the M. hyo antigen has been separated from said antibody; and wherein said composition is obtained by the method of:
A. separating the M. hyo antigen from said antibody by either centrifugation or an immuno-depletion step; wherein the M. hyo antigen is separated from said antibody; and
B. mixing the PCV-2 antigen with the M. hyo antigen separated from said antibody.
2. The ready to use vaccine of claim 1 , wherein the PCV-2 antigen is a PCV-2 ORF2 protein, the M. hyo antigen is a bacterin, or both the PCV-2 antigen is a PCV-2 ORF2 protein and the M. hyo antigen is a bacterin.
3. The ready to use vaccine of claim 2 , wherein the M. hyo antigen is an M. hyo bacterin and the PCV-2 antigen is a PCV-2 ORF2 protein.
4. The ready to use vaccine of claim 2 , wherein said separating of the M. hyo antigen from said antibody is performed by an immuno-depletion step.
5. The ready to use vaccine of claim 4 , wherein said immuno-depletion step is performed with a Protein-G ligand or a Protein-A ligand.
6. The ready to use vaccine of claim 5 , wherein the Protein-G ligand or the Protein-A ligand is bound to a solid phase.
7. The ready to use vaccine of claim 5 , wherein said immuno-depletion step is performed with the Protein-A ligand.
8. The ready to use vaccine of claim 7 , wherein the Protein-A ligand is bound to a solid phase.
9. A ready to use vaccine comprising a porcine circovirus type 2 (PCV-2) antigen and a Mycoplasma hyopneumoniae ( M. hyo ) antigen; wherein the M. hyo antigen originates from media comprising serum that also contains an antibody that is capable of binding to the PCV-2 antigen; and wherein the M. hyo antigen had been separated from said antibody prior to mixing the M. hyo antigen with the PCV-2 antigen to form said ready to use vaccine.
10. The ready to use vaccine of claim 9 , wherein the PCV-2 antigen is a PCV-2 ORF2 protein, the M. hyo antigen is a bacterin, or both the PCV-2 antigen is a PCV-2 ORF2 protein and the M. hyo antigen is a bacterin.
11. The ready to use vaccine of claim 10 , wherein the M. hyo antigen is an M. hyo bacterin and the PCV-2 antigen is a PCV-2 ORF2 protein.
12. The ready to use vaccine of claim 10 , wherein said separating of the M. hyo antigen from said antibody is performed by an immuno-depletion step.
13. The ready to use vaccine of claim 12 , wherein said immuno-depletion step is performed with a Protein-G ligand or a Protein-A ligand.
14. The ready to use vaccine of claim 13 , wherein the Protein-G ligand or the Protein-A ligand is bound to a solid phase.
15. The ready to use vaccine of claim 12 , wherein said immuno-depletion step is performed with the Protein-A ligand.
16. The ready to use vaccine of claim 15 , wherein the Protein-A ligand is bound to a solid phase.